CGM in Prediabetes Prevention Trials: How Real-Time Glucose Feedback Reshapes Behavior in 2026 RCTs

How Do CGM Devices Function as Behavioral Nudges in Prediabetes Trials?

Behavioral science research has long established that immediate, tangible feedback is among the most powerful drivers of habit change. In prediabetes prevention trials, CGM devices exploit this principle by converting abstract dietary advice into concrete, real-time glucose curves that participants can observe on their smartphones within minutes of eating or exercising.

This mechanism draws on self-regulation theory, which posits that individuals are more likely to modify behavior when they can clearly perceive the consequences of their actions. A 2023 narrative review published in The Lancet Digital Health highlighted that wearable health technologies facilitating self-monitoring consistently outperform passive educational interventions in chronic disease prevention contexts. In CGM-based RCTs for prediabetes, participants frequently report that seeing a glucose spike after a specific meal creates a more compelling motivation to change than receiving generalized nutritional counseling alone.

Investigators designing these trials often incorporate structured reflection protocols — asking participants to log observations about their glucose patterns weekly — which reinforces the self-monitoring loop and helps translate short-term awareness into durable behavioral shifts.

What Does the Evidence Say About Long-Term Adherence After CGM Removal?

A central question in prediabetes CGM trials is whether behavioral improvements persist after the monitoring device is removed. If benefits evaporate once the feedback loop disappears, the public health value of CGM as a prevention tool would be substantially diminished.

Early evidence is cautiously optimistic. Data from pilot studies and initial RCT phases suggest that a substantial proportion of participants maintain modified eating patterns and physical activity levels for at least six months after CGM discontinuation. Researchers attribute this to a learning effect — participants internalize which foods and behaviors trigger unfavorable glucose responses, and this knowledge persists even without ongoing monitoring.

However, adherence science from the Diabetes Prevention Program's long-term follow-up, published in The Lancet in 2009, demonstrated that behavioral maintenance diminishes over time without reinforcement. This raises the possibility that intermittent CGM use — periodic monitoring sessions rather than continuous wear — could offer a cost-effective middle ground that maintains behavioral gains while reducing device costs and sensor fatigue.

Are CGM-Based Prevention Programs Cost-Effective Compared to Standard Lifestyle Interventions?

The economic case for CGM in prediabetes hinges on whether the additional device cost — currently several hundred dollars per month without insurance coverage — is offset by reduced downstream healthcare expenditure from prevented diabetes cases. The American Diabetes Association estimates that a person with diagnosed type 2 diabetes incurs average medical expenditures approximately 2.6 times higher than a comparable individual without diabetes.

Several ongoing RCTs have embedded health economic analyses as secondary endpoints, measuring incremental cost-effectiveness ratios that account for device costs, healthcare utilization, and quality-adjusted life years gained. Preliminary modeling published in Diabetes Technology and Therapeutics has suggested that even modest improvements in diabetes conversion rates — on the order of 5–10 percentage points beyond standard lifestyle intervention alone — could render CGM-enhanced prevention programs cost-effective at willingness-to-pay thresholds commonly used by health technology assessment bodies.

Insurance coverage remains the most significant practical barrier. As of early 2026, most U.S. health plans do not cover CGM for individuals without a diabetes diagnosis, creating an access inequity that disproportionately affects lower-income populations who bear the highest prediabetes burden.